Theranostics‎ > ‎

Report 2007-2012

http://www.leaddiscovery.co.uk/reports/261/Theranostics_Report_20072012/

Questions: Discounts, Updates etc.

Pages: 115

Price (Single): £1,499

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2007-01-31

Order Online Now

Theranostics Report 2007-2012

Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but this report can make it a lot easier for you and your company to address them.

This report delivers to you a clear understanding of the commercial prospects of theranostics. The fusion of drug therapy and diagnostics, with the purpose of optimising efficacy and safety, as well as streamlining the process of drug development offers you and your company clear opportunities. This emerging field is generating interest from the healthcare industry and regulatory bodies, with the associated market expanding continually as the importance of theranostics is recognised.

Theranostic solutions are playing an increasingly important role in pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, theranostics is paving the way towards the long-held goal of personalised medicine, to the benefit of patients and payers. Theranostics has also received encouraging support from regulators such as the FDA. Pharmaceutical, diagnostics and biotechnological companies cannot afford to overlook this rapidly emerging field. So you should be sure you corner your percentage of the market immediately.

Theranostics 2007-2012 examines the market for theranostic solutions critically, through comprehensive primary and secondary research. Importantly, visiongain discusses theranostics in the context of the wider diagnostics market. In addition to consultation with experts in industry, this research involved a detailed study of documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting and SWOT analyses. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, this report concentrates on the following essential aspects of the theranostics sector:

  • Technologies that drive the theranostics sector
  • Key industrial players in theranostics - including partnerships in that field
  • Forecasts of the global theranostics market from 2007-2012, including forecasts of the molecular diagnostics market and principal market segments within theranostics
  • Drivers and opportunities in the theranostics sector
  • Restraints and threats in the theranostics sector
  • Assessments of relevant business models, technological solutions and associated issues
  • Coverage of future trends in the sector
  • Insight from a survey with experts from industry and academia

Why you should buy this report: 

  • To receive a comprehensive analysis of the prospects for theranostics from 2007-2012
  • To discover predicted revenues, growth rates and other key metrics for theranostic solutions from 2006-2011
  • To receive the views of experts in the theranostics sector
  • To determine the forces that influence the market for theranostics: Competitive characteristics of the market, Drivers, Restraints, Strengths, weaknesses, opportunities and threats
  • To find out where theranostics is heading - both technologically and commercially

Visiongain predicts that all aspects of theranostics will exhibit strong growth in revenues from 2007-2012, with significant investments being made by far-sighted companies in the pharmaceutical, diagnostics and biotechnological sectors. Although still in its early stages of commercial development, theranostics will increasingly gain acceptance from stakeholders in healthcare. Successful participating companies will benefit as a result, gaining early market prominence from high-value products. But which areas of theranostics will that be? Find out today by ordering your executive copy of Theranostics 2007.

Table of Contents

  • 1 Executive Summary: Theranostics 2007-2012
  • 2 An Introduction to Theranostics
    • 2.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
    • 2.2 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints
    • 2.3 The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market
      • 2.3.1 Reducing Efficiencies in R&D Result in Concerns Over Thinning Pipelines
    • 2.4 Theranostics is Essentially a Fusion of Drug Therapy and Diagnostics
      • 2.4.1 Recent Advances in Biomedical Sciences Have Made Theranostics Possible
      • 2.4.2 Genentech's Herceptin is a Prominent Example of the Theranostics Approach
      • 2.4.3 Diagnostics is Now Increasingly Reliant on Genetic and Protein-Based Markers
      • 2.4.4 Recent FDA Publication Places Increasing Importance on Theranostics
    • 2.5 The Human Genome Project Has Provided Important Scope for Pharmaceutical Development - Genomics and Proteomics
      • 2.5.1 Pharmacogenomics is Increasingly Relevant to Pharmaceutical Development
      • 2.5.2 Proteomics Constitutes the "Next Step" After Genomics
    • 2.6 Advanced Diagnostics and Personalised Medicine
      • 2.6.1 The Dawn of Pharmacogenomic Medicine
      • 2.6.2 Personalised Medicine Will Rely Heavily Upon Theranostics
    • 2.7 The Market for Theranostic Products is Creating Opportunities for Pharmaceutical and Diagnostic Companies
    • 2.8 While Medical Stakeholders Will Benefit from Theranostics, Concerns Over Privacy Likely to Impede Progress
  • 3 Key Players in the Theranostics Field
    • 3.1 Genentech's Herceptin and Novartis' Gleevec are Probably the Best Known Examples of a Theranostic Approach in Use
    • 3.2 PharmaNetics' Thrombolytic Assessment System - Pioneers in the Field
    • 3.3 Genentech and DakoCytomation: Herceptin and HercepTest
    • 3.4 ImClone Systems and DakoCytomation: Erbitux and EGFR pharmDx Test
    • 3.5 Abbott Laboratories' PathVysion HER-2 DNA Probe Kit
    • 3.6 Bayer's ADVIA Centaur Immunoassay System - An Early Entrant to the Theranostics Market
    • 3.7 Novartis and Ventana Medical Systems: Gleevec and VentanaDx c-Kit
    • 3.8 Roche's Diagnostics Division: The AmpliChip CYP450 Array
    • 3.9 Innogenetics
    • 3.10 A&G Pharmaceutical a Leading Participant in the Monoclonal Theranostics Field
    • 3.11 HBV Theranostica
    • 3.12 Visible Genetics' Pharmacogenomic HIV Drug Resistance Test
    • 3.13 NGI An Industry Leader in Blood Plasma Nucleic Acid Testing
    • 3.14 Investigen's SmartDNA a New Diagnostic Tool
    • 3.15 Lpath Therapeutics Merges With Public Company
    • 3.16 Itsi-Biosciences
    • 3.17 Amorfix Life Sciences and Biogen Idec Collaborate on Research for ALS disease
    • 3.18 Clinical Data's DNA-based Diagnostic and Therapeutic Products
      • 3.18.1 Vilazodone
      • 3.18.2 PGxTest:WARFARIN
    • 3.19 Axis-Shield
    • 3.20 Conclusions
  • 4 Forecast of the Market for Theranostics, 2007-2012
    • 4.1 Molecular Diagnostics Will Contribute an Increasing Proportion of Revenues Within The World In Vitro Diagnostics Market
    • 4.2 Theranostics Will Exhibit Rapid Market Growth from 2007-2012
    • 4.3 Drug Toxicity Testing, Oncology and Infection Segments Will Contribute the Highest Revenues to the World Theranostics Market from 2006-2012
    • 4.4 Personalised Medicine Will Become More Prominent in Healthcare With Theranostics Benefiting as a Result
      • 4.4.1 The Completion of the Human Genome Project Has Been a Major Driver of Molecular Diagnostics
    • 4.5 Industry Has Been Relatively Slow to Adopt Theranostics - But That Situation Is Changing
      • 4.5.1 Will The Success of Theranostics Lead To a Shift in Spending From Drugs to Diagnostics?
    • 4.6 Theranostics Will Take Off In a Few Important Therapy Areas First
      • 4.6.1 Cancer Diagnostic Technologies Constitute a Particularly Important Application
    • 4.7 The Improvement in Clinical Performance from Theranostics Will Make It Easier To Justify The Costs to Payers
      • 4.7.1 A Theranostic Combination Can Provide an Important Competitive Advantage During This Emergent Period
    • 4.8 Personalised Medicine Supported By Theranostics Could Supersede the Existing Blockbuster Model, With Sustainable Revenue Flows Continuing
    • 4.9 The Market for Theranostic Products Is Creating Significant Opportunities for Many Companies in the Pharmaceutical, Diagnostics and Biotechnological Sectors
      • 4.9.1 Rising Insurance Coverage Will Benefit the Market
    • 4.10 The FDA and Other Agencies Have Expressed Significant Interest in Theranostics
    • 4.11 Inter-Industry Will Continue to Drive the Theranostics Market
    • 4.12 Biomarker Technology is Still Emerging - But The Technological and Commercial Potential Remains Very Significant
      • 4.12.1 While The Prospects for Clinical Studies Are Good, Concerns Over Privacy May Impede Progress
    • 4.13 Several Key Factors Are Required for Success in the Theranostics Market
  • 5 Discussion of Issues Affecting Theranostic Applications
    • 5.1 A SWOT Analysis for Theranostics
    • 5.2 Theranostic Solutions Will Continue To Expand Their Presence in the Pharmaceutical Industry
    • 5.3 Theranostic Applications Face No Significant Restraints to Their Continuing Adoption Within the Pharmaceutical Sector
    • 5.4 Theranostics will Benefit from FDA's Guidance on Pharmacogenomic Data Submission
      • 5.4.1 Distinguishing Patients at a Greater Risk is Vital
      • 5.4.2 In Future Parallel Use of Markers and Drugs Will Become Prevalent
    • 5.5 The EDMA Cites Theranostics as a Medium-to-Long-Term Driver for Healthcare
    • 5.6 Personalised Medicine is a Strong Driver of the Theranostics Sector
      • 5.6.1 While Personalised Medicine Is Still A Goal for the Future, The Technology Is Already Emergent
    • 5.7 Identifying Suitable Biomarkers Remains a Significant Challenge
    • 5.8 Theranostics Bill Introduced in the US Senate During 2006
    • 5.9 Funding for Theranostics R&D Efforts May Be Limited by Low Reimbursement Rates
    • 5.10 Cancer Diagnostics is an Important Growth Area With Relevance to Theranostics
    • 5.11 Collaboration Among Stakeholders is Essential
    • 5.12 Nucleic Acid Testing Technologies Will Be Decisive in the Development of the Theranostics Market
    • 5.13 The Outlook for Theranostics
  • 6 Current and Future Developments in Theranostics - The Views of Experts in the Field
    • 6.1 How Influential Will Theranostics Be In Coming Years?
    • 6.2 Are Pharmaceutical and Diagnostic Companies Ready for Closer Links?
    • 6.3 Will Theranostics Contribute Significantly to Clinical Trials?
    • 6.4 In What Areas Will Theranostics Be Most Prominent?
  • 7 Conclusions
    • 7.1 Theranostics is Essentially a Fusion of Drug Therapy and Diagnostics
    • 7.2 Theranostics Will Exhibit Rapid Market Growth from 2007-2012
    • 7.3 Drug Toxicity Testing, Oncology and Infection Segments Will Contribute the Highest Revenues to the World Theranostics Market from 2006-2012
    • 7.4 Theranostics Constitute A Significant Market Opportunity for The Healthcare Industry

  • List of Tables
  • Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
  • Table 4.1 The World Market for In Vitro Diagnostics ($bn) Showing Revenues for Molecular and Theranostic Applications, 2006-2012
  • Table 4.2 Share (%) of the World In Vitro Diagnostics Market Held by Molecular Diagnostics, 2006 & 2012
  • Table 4.3 Share (%) of the World Molecular Diagnostics Market Held by Theranostics, 2006 & 2012
  • Table 4.4 Revenues ($m) and Growth (%) for Components of the World Theranostics Market, 2006-2012
  • Table 4.5 Market Shares and CAGRs for Applications Within the Theranostics Sector, 2006-2012
  • Table 5.1 A SWOT Chart for Theranostic Applications, 2007-2012

  • List of Figures
  • Figure 2.1 The Increasing Average Cost ($m) of NCE Development, 1976-2005
  • Figure 4.1 The World Market for In Vitro Diagnostics ($bn) Showing Revenues for Molecular and Theranostic Applications, 2006-2012
  • Figure 4.2 Share (%) of the World In Vitro Diagnostics Market Held by Molecular Diagnostics, 2006
  • Figure 4.3 Share (%) of the World In Vitro Diagnostics Market Held by Molecular Diagnostics, 2012
  • Figure 4.4 World Revenues ($m) for Theranostic Applications, 2006-2012
  • Figure 4.5 Share (%) of the World Molecular Diagnostics Market Held by Theranostics, 2006
  • Figure 4.6 Share (%) of the World Molecular Diagnostics Market Held by Theranostics, 2012
  • Figure 4.7 Revenues ($bn) from Theranostics Compared With Those of the World In Vitro Diagnostics Market, 2006-2012
  • Figure 4.8 Revenues ($bn) from Theranostics Compared With Those of the World Molecular Diagnostics Market, 2006-2012
  • Figure 4.9 Share (%) of the World In Vitro Diagnostics Market Held by Theranostics, 2006-2012
  • Figure 4.10 Share (%) of the World Molecular Diagnostics Market Held by Theranostics, 2006-2012
  • Figure 4.11 Revenues ($m) for Components of the World Theranostics Market, 2006-2012
  • Figure 4.12 Components of the World Theranostics Market - Lower Revenues ($m) In Detail, 2006-2012
  • Figure 4.13 CAGR Values (%) for Market Segments Within the Theranostics Sector, 2006-2012
  • Figure 4.14 Percentage Share (%) of The World Theranostics Market Held By Component Market Segments, 2006
  • Figure 4.15 Percentage Share (%) of The World Theranostics Market Held By Component Market Segments, 2012
  • Figure 4.16 Theranostics: Revenues ($m) for Cardiovascular Applications, 2006-2012
  • Figure 4.17 Theranostics: Revenues ($m) for Oncological Applications, 2006-2012
  • Figure 4.18 Theranostics: Revenues ($m) for Infection-Based Applications, 2006-2012
  • Figure 4.19 Theranostics: Revenues ($m) for CNS Applications, 2006-2012
  • Figure 4.20 Theranostics: Revenues ($m) for Metabolic Applications, 2006-2012
  • Figure 4.21 Theranostics: Revenues ($m) for Other Applications, 2006-2012
  • Figure 4.22 Theranostics: Revenues ($m) for Toxicological Applications in Clinical Studies, 2006-2012
  • Other users found this report page using the following search terms: Theranosticsdiagnostics theranostics theranostic market diagnostics diagnostic reimbursementfda molecular vitro uk

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.



    Comments